Table 1.
Human population survey results
|
Urinogenital schistosomiasis |
Intestinal schistosomiasis |
||||||
|---|---|---|---|---|---|---|---|
| Urine filtration positive (n/N) | Median posterior prevalence (BCI) | Proportion of infected individuals with Schistosoma haematobium miracidia (n*) | Proportion of infected individuals with hybrid miracidia (n*) | Intensity of infection (median number of eggs per 10 mL [IQR; range]) | Kato-Katz positive (n/N) | Median posterior prevalence (BCI) | |
| Richard Toll and Lac de Guiers, 2016 | |||||||
| Children | 264/375 | 0·87 (0·80–0·94) | 0·94 (168) | 0·63 (168) | 28 (6–90; 1–990) | 45/318 | 0·20 (0·14–0·32) |
| Adults | 13/20 | 0·79 (0·52–0·97) | 1 (4) | 0·5 (4) | 5 (3–8; 1–58) | 0/20 | 0·05 (0·00–0·24) |
| Richard Toll and Lac de Guiers, 2017–18 | |||||||
| Children | 275/386 | 0·88 (0·82–0·95) | 0·91 (166) | 0·72 (166) | 10·5 (2–41; 1–433) | 35/292 | 0·17 (0·11–0·28) |
| Adults | 29/88 | 0·41 (0·30–0·54) | 0·85 (14) | 1 (14) | 2 (1–26; 1–48) | 0/41 | 0·02 (0·00–0·13) |
| Barkedji and Linguère, 2016 | |||||||
| Children | 48/201 | 0·30 (0·23–0·38) | 1 (36) | 0·11 (36) | 17 (6–65; 1–500) | 0/203 | 0·00 (0·00–0·03) |
| Adults | 22/107 | 0·26 (0·17–0·36) | 1 (14) | 0·21 (14) | 3 (1–20, 1–295) | 0/111 | 0·01 (0·00–0·05) |
| Barkedji and Linguère, 2017–18 | |||||||
| Children | 109/323 | 0·42 (0·35–0·49) | 1 (54) | 0·09 (54) | 30 (2–113; 1–500) | 0/289 | 0·00 (0·00–0·02) |
| Adults | 32/85 | 0·47 (0·34–0·60) | 1 (16) | 0 (16) | 6 (3–20; 1–200) | 0/58 | 0·02 (0·00–0·09) |
Summary of human population surveys in Richard Toll and Lac de Guiers, and Barkedji and Linguère, in 2016 and 2017–18, including Bayesian estimation of prevalence of urinary and intestinal schistosomiasis. Median Schistosoma eggs per mL of urine is given as an indicator of infection intensity. Children were aged 5–17 years and adults aged 18–78 years. BCI=Bayesian credible interval.
n represents the number of positive individuals for whom molecular material was analysed.